Welcome to our dedicated page for MURPHY CANYON ACQUISITION news (Ticker: MURFU), a resource for investors and traders seeking the latest updates and insights on MURPHY CANYON ACQUISITION stock.
Murphy Canyon Acquisition Corp. (Nasdaq: MURF) is progressing toward completing a business combination with Conduit Pharmaceuticals Limited to form Conduit Pharmaceuticals Inc., leveraging an efficient model for developing Phase II-ready therapeutic compounds. Led by pharmaceutical veterans Dr. David Tapolczay and Dr. Freda Lewis-Hall, the company targets assets with clear clinical pathways and partnership potential.
This page provides investors with essential updates on the merger process, including the transition to Nasdaq symbols CDT (common stock) and CDTTW (warrants). Find verified information on clinical trial developments, licensing agreements, executive appointments, and regulatory milestones. All content is sourced from official filings and corporate communications.
As a subsidiary of Presidio Property Trust, Inc. through its sponsor, Murphy Canyon maintains focus on transparent shareholder communication during this transition. Regularly updated coverage ensures stakeholders stay informed about value-driving events without time-intensive research.
Bookmark this page for streamlined access to merger completion updates and post-combination corporate strategy. Check back for new developments as Murphy Canyon evolves into a clinical-stage pharmaceutical entity under the Conduit brand.
Murphy Canyon Acquisition Corp. closed its initial public offering (IPO) of 13,225,000 units at $10.00 per unit, including an over-allotment of 1,725,000 units. The units began trading on NASDAQ under the ticker MURFU on February 3, 2022. Each unit consists of one share of common stock and one redeemable warrant, with warrants exercisable at $11.50. The company targets real estate businesses with a combined enterprise value of $300 million to $1.2 billion. The offering was managed by A.G.P./Alliance Global Partners and co-managed by The Benchmark Company.
Murphy Canyon Acquisition Corp. (NASDAQ:MURFU) has announced that its IPO underwriters fully exercised the over-allotment option, resulting in the purchase of an additional 1,725,000 units at $10.00 each. This brings total gross proceeds to $132.25 million. Each unit consists of one share of Class A common stock and a redeemable warrant for one additional share at $11.50. The units began trading on February 3, 2022. The company targets mergers and acquisitions within the real estate sector, aiming for a combined enterprise value of $300 million to $1.2 billion.
Murphy Canyon Acquisition Corp. announced the pricing of its initial public offering (IPO) of 11,500,000 units at $10.00 per unit, which includes one share of common stock and one redeemable warrant. Trading is set to begin on February 3, 2022 on NASDAQ under the ticker symbol MURFU, with the IPO expected to close on February 7, 2022. The company targets businesses in the real estate sector, aiming for an aggregate enterprise value of $300 million to $1.2 billion for potential mergers or acquisitions.
